Doctor of Medicine, Chief Physician. Completed undergraduate, master's, and doctoral studies at Peking University Health Science Center, postdoctoral fellow in oncology at the University of Maryland, USA, and a state-sponsored visiting scholar at Johns Hopkins University, USA. Specializes in the medical pharmacotherapy and multidisciplinary comprehensive treatment of thoracic tumors, including lung cancer, malignant pleural mesothelioma, and thymic tumors. Has extensive experience in the clinical application, research frontiers, and adverse event management of novel anti-tumor drugs such as chemotherapy, molecular targeted drugs, immunotherapies, and antibody-drug conjugates. Research areas include the mechanisms of lung cancer pathogenesis, resistance mechanisms and efficacy prediction of molecular targeted drugs in lung cancer, dynamic monitoring of drug resistance, and immunotherapy for malignant mesothelioma and its molecular basis. Holds positions including Chair of the Molecular Targeted Therapy Committee of the Beijing Association for Chronic Disease Prevention and Health Education, Vice Chair of the Multidisciplinary Integration Committee for Central Nervous System Metastases of the Beijing Association of Integrative Medicine, Member of the Malignant Mesothelioma Committee of the Chinese Anti-Cancer Association, Member of the Tumor Biomarker Expert Committee of CSCO, and Standing Committee Member of the Lung Cancer Committee of the Beijing Oncology Society. In recent years, has led multiple research projects, including the National Natural Science Foundation of China, the "Young Seedling" Talent Project of the Beijing Hospital Authority, the Specialized Research Fund for the Doctoral Program of Higher Education of the Ministry of Education, the CSCO Research Fund General Project, and several international and domestic multi-center clinical trials. Has published multiple papers as first/co-author in SCI-indexed and domestic core journals. Has participated in receiving awards including the CSCO China Clinical Oncology Science Fund "Excellent Paper Award," the Second Prize for Scientific and Technological Progress in Higher Education Institutions, the First Prize for Scientific and Technological Progress from the Chinese Anti-Cancer Association, and the Second Prize for Huaxia Medical Science and Technology.